ME3183 is an oral unselective PDE4 inhibitor developed by Meiji Pharma USA Inc. to treat psoriasis, with potential for use in additional inflammatory conditions like AD in the near future [131,132]. This evidence concerns the gene PDE4A and Alzheimer disease.